SK Bioscience (302440 KS): IDT Drives Strong 3Q Performance; Operating Loss Narrows
​SK Bioscience sees ~2.5x revenue growth and reduced operating loss in 3Q25, driven by strong performance of IDT Biologika. Strong base business...
534 Views
APAC Healthcare Weekly (December 21)–Fosun Pharma, Hansoh, Daiichi Sankyo, Takeda, Hanmi, Max Health
Fosun Pharma is acquiring 53% stake in Green Valley. Hansoh inked exclusive license agreement with Glenmark Pharma. Daiichi Sankyo’s Enhertu got...
328 Views
SK Chemicals: A Potential EB Issue of 240 Billion Won Using Its Stake in SK Bioscience
Hankyung Business Daily reported today that SK Chemicals (285130 KS) is pursuing an issuance of exchangeable bonds (EB) worth 240 billion won using...
438 Views
SK Bioscience (302440 KS): Strong Base Business and IDT Contribution Drive 2Q25 Performance
​SK Bioscience reports business recovery with 2Q25 base business revenue up 22% YoY. IDT Biologika revenue is increasing sequentially. The company...
379 Views
SK Bioscience (302440 KS): Dual Engines Led Growth Strategy Is on Track; Solid 1Q25 Performance
​SK Bioscience initiates global Phase 3 trial of PCV21 vaccine. IDT Biologika shows revenue growth in 1Q25, on track to meet 2025 guidance. 1Q25...
329 Views